RN765C, a low affinity EGFR antibody drug conjugate with potent anti-tumor activity in preclinical solid tumor models.

Autor: Wong OK; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; Allogene Therapeutics, South San Francisco, CA, USA., Tran TT; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; NGM Biopharmaceuticals, South San Francisco, CA, USA., Ho WH; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; Alector Inc., South San Francisco, CA, USA., Casas MG; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; acib GmbH Graz, Graz, Austria., Au M; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; Allogene Therapeutics, South San Francisco, CA, USA., Bateman M; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA., Lindquist KC; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA., Rajpal A; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; Bristol-Myers Squibb, Redwood City, CA, USA., Shelton DL; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA., Strop P; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; Bristol-Myers Squibb, Redwood City, CA, USA., Liu SH; Oncology R&D, Cancer Immunology Discovery Unit, Pfizer Inc., South San Francisco, CA, USA.; Abmart Inc., Redwood City, CA, USA.

Publikováno v: Oncotarget [Oncotarget] 2018 Sep 11; Vol. 9 (71), pp. 33446-33458. Date of Electronic Publication: 2018 Sep 11 (Print Publication: 2018).

Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading.

Autor: Strop P; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Delaria K; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Foletti D; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Witt JM; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Hasa-Moreno A; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Poulsen K; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Casas MG; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Dorywalska M; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Farias S; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Pios A; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Lui V; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Dushin R; Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut, USA., Zhou D; Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut, USA., Navaratnam T; Worldwide Medicinal Chemistry, Pfizer Inc., Groton, Connecticut, USA., Tran TT; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Sutton J; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Lindquist KC; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Han B; Drug Safety Research and Development, Pfizer Inc., San Diego, California, USA., Liu SH; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Shelton DL; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Pons J; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA., Rajpal A; Rinat Laboratories, Pfizer Inc., South San Francisco, California, USA.

Publikováno v: Nature biotechnology [Nat Biotechnol] 2015 Jul; Vol. 33 (7), pp. 694-6.

Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates.

Autor: Strop P; Rinat-Pfizer, 230 East Grand Avenue, South San Francisco, CA 94080, USA. pavel.strop@pfizer.com, Liu SH, Dorywalska M, Delaria K, Dushin RG, Tran TT, Ho WH, Farias S, Casas MG, Abdiche Y, Zhou D, Chandrasekaran R, Samain C, Loo C, Rossi A, Rickert M, Krimm S, Wong T, Chin SM, Yu J, Dilley J, Chaparro-Riggers J, Filzen GF, O'Donnell CJ, Wang F, Myers JS, Pons J, Shelton DL, Rajpal A

Publikováno v: Chemistry & biology [Chem Biol] 2013 Feb 21; Vol. 20 (2), pp. 161-7.

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9.

Autor: Chaparro-Riggers J; Rinat-Pfizer Inc., South San Francisco, California 94080, USA., Liang H, DeVay RM, Bai L, Sutton JE, Chen W, Geng T, Lindquist K, Casas MG, Boustany LM, Brown CL, Chabot J, Gomes B, Garzone P, Rossi A, Strop P, Shelton D, Pons J, Rajpal A

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2012 Mar 30; Vol. 287 (14), pp. 11090-7. Date of Electronic Publication: 2012 Jan 31.